Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$31.0 million.

  • Voyager Therapeutics' Cash from Operations fell 1101.26% to -$31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$116.7 million, marking a year-over-year decrease of 37566.52%. This contributed to the annual value of -$15.3 million for FY2024, which is 11964.86% down from last year.
  • As of Q3 2025, Voyager Therapeutics' Cash from Operations stood at -$31.0 million, which was down 1101.26% from -$33.3 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Cash from Operations high stood at $123.6 million for Q1 2023, and its period low was -$37.9 million during Q1 2025.
  • In the last 5 years, Voyager Therapeutics' Cash from Operations had a median value of -$20.7 million in 2021 and averaged -$5.6 million.
  • As far as peak fluctuations go, Voyager Therapeutics' Cash from Operations soared by 26167.0% in 2022, and later crashed by 368203.59% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Cash from Operations (Quarter) stood at $11.2 million in 2021, then crashed by 209.37% to -$12.2 million in 2022, then plummeted by 94.05% to -$23.8 million in 2023, then soared by 38.85% to -$14.5 million in 2024, then plummeted by 113.7% to -$31.0 million in 2025.
  • Its Cash from Operations stands at -$31.0 million for Q3 2025, versus -$33.3 million for Q2 2025 and -$37.9 million for Q1 2025.